We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See.
- Authors
Pischel, Lauren; Goshua, George
- Abstract
The article discusses cost-effectiveness of Tocilizumab in severe coronavirus disease 2019. It mentions cost-effectiveness of combination therapy with tocilizumab and dexamethasone; and also mentions mortality benefit seen with combination therapy in severe COVID-19 is largely sufficient to justify tocilizumab expense, from a health system perspective in the U.S.
- Subjects
INTERLEUKINS; DECISION trees; COVID-19; TOCILIZUMAB; SEVERITY of illness index; COST effectiveness; CHEMICAL inhibitors
- Publication
Clinical Infectious Diseases, 2021, Vol 73, Issue 11, p2119
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciab459